New tarriffs have caused extreme volatility in the markets.

But a handful of sectors are still thriving, including biotech stocks, thanks to booming merger and acquisition activity, an aging population, and impressive new innovations.

Look at Mirati Therapeutics (MRTX), which is a clinical-stage oncology company developing targeted product candidates to address the genetic, epigenetic and immunological promoters of cancer. Its precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients, who are most likely to benefit from targeted drug treatment.

The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate is the KRAS G12C inhibitor program to address mutations and tumors.

MRTX has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products.

We recommended MRTX at $3.30 a year ago. The stock just hit a high of $54.64 this month, handing us a potential win of 1,556%.  That’s an incredible gain in a little over a year.

All as the company advances its clinical programs to improve the immune environment of tumor cells that may enhance and expand the efficacy of existing immunotherapy medicines. Its pre-clinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where very few treatment options exist.

What’s even more exciting, analysts at Citi just raised their price target on MRTX to $64 on positive interim Phase II data, reflecting their increased conviction on sitravatinib plus nivolumab in IO refractory non-small-cell lung cancer patients.

Interesting to note, this stock was discounted by most investors when we found MRTX.

We were actually shocked that others chose to ignore a stock like this, even though it had sizable catalysts. Unbelievably, there are plenty of other opportunities just like this that other investors are avoiding.

But we’re not.

In fact, we just featured a new biotech opportunity in the July 2018 issue of The Cheap Investor that was just recently posted on our website.